Welcome to our dedicated page for Aspira Womens Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspira Women's Health Inc. filings document the public-company record for a women's health diagnostics business focused on noninvasive gynecologic disease testing. Recent Form 8-K reports cover executive appointments, laboratory-services agreements, secured borrowing, equity-purchase arrangements, investor-presentation disclosures, and other material events involving the company's common stock and operating relationships.
Proxy materials describe board matters, executive compensation, equity awards, and shareholder voting items. Registration statements and related agreements disclose securities offerings, resale registration matters, common stock terms, filer status, and capital-structure effects. The filing record also includes a Form 12b-25 notice related to timing of the annual report and accounting completion for Aspira's Form 10-K.
Aspira Women’s Health Inc. reported Q1 2026 results showing fragile finances despite an accounting profit. Revenue from its OvaSuite diagnostic tests was $1.967M, down from $2.279M a year earlier, and the company recorded a loss from operations of $2.203M.
Net income was $0.676M, driven mainly by a non‑cash $3.11M gain from revaluing warrant liabilities, along with higher interest expense. Cash and cash equivalents were only $1.344M against total liabilities of $11.295M and a working capital deficit of about $1.81M, leading management to state there is “substantial doubt” about its ability to continue as a going concern.
The company was delisted from Nasdaq in 2025 and now trades on the OTC QX Market. To fund operations, it relies on high‑cost debt, including a subordinated loan with a 42% interest rate, and equity facilities such as a $10M purchase agreement with Lincoln Park, of which $7k was used in Q1.
Aspira Women’s Health Inc. appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026, replacing Brian Hungerford, who stepped down for personal reasons. Strahley will work in a fractional role, committing at least twenty hours per week.
Under his Executive Employment Agreement, Strahley receives an annualized base salary of $167,000 and is eligible for the company’s 401(k) plan but not for group insurance benefits. The Board will approve stock options for 70,000 shares at fair market value on the grant date, with 25% vesting ninety days after his start date and the remainder vesting monthly over the following nine months. Any unvested options fully vest upon a Change in Control, and his at-will employment includes no severance beyond accrued obligations.
Aspira Women’s Health Inc. is asking stockholders to vote at its June 17, 2026 annual meeting in Houston on four main items. Stockholders will elect six directors for one-year terms, hold an advisory "say-on-pay" vote on executive compensation, and consider an amendment to the 2019 Stock Incentive Plan to add 5,000,000 shares, increasing the total authorized under the plan to 9,532,818 shares and raising the cap on incentive stock options to 15,000,000 shares. They will also vote on ratifying BDO USA, P.C. as independent auditor for 2026. The record date is April 20, 2026, when 43,500,411 common shares were outstanding. The proxy describes board structure, committee work, director and executive pay, and change-in-control severance protections.
Aspira Women’s Health Inc. reports that there is substantial doubt about its ability to continue as a going concern, citing an accumulated deficit of $544.177 million and insufficient capital to fund operations through 2026. The company is pursuing strategic alternatives and new financing after converting $1.365 million of senior secured convertible notes into equity units in March 2025. Aspira lost a key non-dilutive funding source when its ENDOinform contract with ARPA-H was terminated after paying $2.0 million in late 2024 and $1.5 million in early 2025, which may delay commercialization of its endometriosis test. Its shares were delisted from Nasdaq in April 2025 for failing listing standards and now trade on the OTC QX Market under the symbol AWHL. The business remains focused on AI-powered gynecologic diagnostics, including Ova1Plus and OvaWatch, with 22,515 OvaSuite tests performed in 2025 and Medicare reimbursement for Ova1 and OvaWatch at $897 per test.
Aspira Women’s Health Inc. notified the SEC it could not timely file its Annual Report on Form 10-K for the period ended December 31, 2025. The company states it needs additional time to complete accounting and disclosures related to its tax provision for the year ended December 31, 2025 and expects to file the Form 10-K within the 15 calendar day extension period. The notification is dated April 1, 2026 and lists Brian Hungerford, CFO as the contact.
Aspira Women’s Health Inc. filed an amended report to provide the full Laboratory Services Agreement it entered into with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories. The agreement is effective as of December 16, 2025 and had previously been disclosed as a material definitive agreement.
The amendment mainly adds the agreement as Exhibit 10.1 after completing redactions of private or confidential information. No financial results or other business updates are included beyond this contract filing.
Aspira Women’s Health Inc. entered into a new subordinated secured term loan agreement with Agile Lending, LLC and other lenders. The company issued a subordinated secured promissory note with $1,050,000 principal and total interest charges of $441,000 (assuming timely payments), maturing on August 26, 2026. The loan is subordinated to all senior indebtedness and is secured by a continuing security interest in substantially all personal property of the company and certain subsidiary co-borrowers, subject to customary exclusions. Proceeds will be used for general corporate purposes, and the agreement contains customary covenants and events of default that allow lenders to accelerate obligations and enforce on collateral if triggered.
Aspira Women’s Health Inc. is registering 16,697,509 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a committed equity financing arrangement. The registered shares include up to 15,873,016 shares that Aspira may sell to Lincoln Park over 24 months under a $10.0 million purchase agreement, plus 824,493 commitment shares already issued as a fee. Aspira will not receive proceeds from Lincoln Park’s resale of these shares, but can raise up to $10.0 million in gross proceeds from its own future sales of purchase shares to Lincoln Park, at prices tied to the market price of its stock. The company highlights potential dilution and stock price pressure from these issuances and resales, notes that its stock trades on the OTCQX under the symbol AWHL, and describes significant trading volatility and governance provisions that may affect control and liquidity.